Stephen A Hill

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11208536/publications.pdf

Version: 2024-02-01

36	1,114	361413	395702
papers	citations	20 h-index	33 g-index

38	38	38	1550
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Green fluorescent carbon dots as targeting probes for LEDâ€dependent bacterial killing. Nano Select, 2022, 3, 662-672.	3.7	5
2	Photosynthesis and crop productivity are enhanced by glucoseâ€functionalised carbon dots. New Phytologist, 2021, 229, 783-790.	7.3	32
3	Comparison of two biomarker only algorithms for early risk stratification in patients with suspected acute coronary syndrome. International Journal of Cardiology, 2020, 319, 140-143.	1.7	12
4	Clinical evaluation of Ortho Clinical Diagnostics high-sensitivity cardiac Troponin I assay in patients with symptoms suggestive of acute coronary syndrome. Clinical Biochemistry, 2020, 80, 48-51.	1.9	14
5	Using the clinical chemistry score in the emergency department to detect adverse cardiac events: a diagnostic accuracy study. CMAJ Open, 2020, 8, E676-E684.	2.4	15
6	Selective photothermal killing of cancer cells using LED-activated nucleus targeting fluorescent carbon dots. Nanoscale Advances, 2019, 1, 2840-2846.	4.6	30
7	Performance of high-sensitivity cardiac troponin in the emergency department for myocardial infarction and a composite cardiac outcome across different estimated glomerular filtration rates. Clinica Chimica Acta, 2018, 479, 166-170.	1.1	17
8	High-sensitivity cardiac troponin concentrations at emergency department presentation in females and males with an acute cardiac outcome. Annals of Clinical Biochemistry, 2018, 55, 604-607.	1.6	3
9	Evaluation of the Siemens ADVIA Centaur high-sensitivity cardiac troponin I assay in serum. Clinica Chimica Acta, 2018, 487, 216-221.	1.1	27
10	Surface functionalisation significantly changes the physical and electronic properties of carbon nano-dots. Nanoscale, 2018, 10, 13908-13912.	5.6	28
11	Multicenter comparison of imprecision at low concentrations of two regulatory approved high-sensitivity cardiac troponin I assays. Clinica Chimica Acta, 2018, 486, 219-220.	1.1	10
12	Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department. Cmaj, 2018, 190, E974-E984.	2.0	38
13	Economic Considerations of Early Rule-In/Rule-Out Algorithms for The Diagnosis of Myocardial Infarction in The Emergency Department Using Cardiac Troponin and Glycemic Biomarkers. Clinical Chemistry, 2017, 63, 593-602.	3.2	11
14	High-Sensitivity Cardiac Troponin Risk Cutoffs for Acute Cardiac Outcomes at Emergency Department Presentation. Canadian Journal of Cardiology, 2017, 33, 898-903.	1.7	20
15	A laboratory score at presentation to rule-out serious cardiac outcomes or death in patients presenting with symptoms suggestive of acute coronary syndrome. Clinica Chimica Acta, 2017, 469, 69-74.	1.1	8
16	Rule-In and Rule-Out of Myocardial Infarction Using Cardiac Troponin and Glycemic Biomarkers in Patients with Symptoms Suggestive of Acute Coronary Syndrome. Clinical Chemistry, 2017, 63, 403-414.	3.2	36
17	Analytical comparison of three different versions of a high-sensitivity cardiac troponin I assay over 10 years. Clinica Chimica Acta, 2017, 475, 51-55.	1.1	25
18	Three-minute synthesis of sp³nanocrystalline carbon dots as non-toxic fluorescent platforms for intracellular delivery. Nanoscale, 2016, 8, 18630-18634.	5.6	61

#	Article	IF	Citations
19	Acceptable Analytical Variation May Exceed High-Sensitivity Cardiac Troponin I Cutoffs in Early Rule-Out and Rule-In Acute Myocardial Infarction Algorithms. Clinical Chemistry, 2016, 62, 887-889.	3.2	47
20	An approach to rule-out an acute cardiovascular event or death in emergency department patients using outcome-based cutoffs for high-sensitivity cardiac troponin assays and glucose. Clinical Biochemistry, 2015, 48, 282-287.	1.9	12
21	Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. Heart Failure Reviews, 2014, 19, 421-438.	3.9	91
22	BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Failure Reviews, 2014, 19, 453-470.	3.9	164
23	Incremental predictive value of natriuretic peptides for prognosis in the chronic stable heart failure population: a systematic review. Heart Failure Reviews, 2014, 19, 521-540.	3.9	18
24	Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review. Heart Failure Reviews, 2014, 19, 507-519.	3.9	22
25	Comparison of hs-cTnI, hs-cTnT, hFABP and GPBB for identifying early adverse cardiac events in patients presenting within six hours of chest pain-onset. Clinica Chimica Acta, 2013, 419, 39-41.	1.1	13
26	Implications of adjustment of high-sensitivity cardiac troponin T assay. Clinical Chemistry, 2013, 59, 574-576.	3.2	32
27	Biomarkers for Predicting Serious Cardiac Outcomes at 72 Hours in Patients Presenting Early after Chest Pain Onset with Symptoms of Acute Coronary Syndromes. Clinical Chemistry, 2012, 58, 298-302.	3.2	22
28	Intra-individual variability in troponin T concentration in dialysis patients. Clinical Biochemistry, 2009, 42, 991-995.	1.9	11
29	Evidence for the use of B-type natriuretic peptides for screening asymptomatic populations and for diagnosis in primary care. Clinical Biochemistry, 2008, 41, 240-249.	1.9	22
30	A systematic review of BNP as a predictor of prognosis in persons with coronary artery disease. Clinical Biochemistry, 2008, 41, 260-265.	1.9	32
31	Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome. Cmaj, 2005, 172, 1685-1690.	2.0	61
32	Can troponin I measurement predict short-term serious cardiac outcomes in patients presenting to the emergency department with possible acute coronary syndrome?. Canadian Journal of Emergency Medicine, 2004, 6, 22-30.	1.1	8
33	Effect of Rheumatoid Factor on Cardiac Troponin I Measurement Using Two Commercial Measurement Systems. Clinical Chemistry, 2000, 46, 307-308.	3.2	29
34	Cholesteryl Ester Transfer Protein Mutations, Protein Activity and HDL-Cholesterol Concentration. Clinical Chemistry and Laboratory Medicine, 1998, 36, 629-32.	2.3	5
35	Mutations in cholesteryl ester transfer protein and hepatic lipase in a North American population. Clinical Biochemistry, 1997, 30, 413-418.	1.9	25
36	Reverse Cholesterol Transportâ€"A Review of the Process and Its Clinical Implications. Clinical Biochemistry, 1997, 30, 517-525.	1.9	107